Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 18/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 18/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.60 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597386 | 0.90 | PSEN1 (0.54) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL4597117 | 0.88 | PSEN1 (0.72) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL4597681 | 0.87 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL4597484 | 0.85 | PSEN1 (0.52) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL4597051 | 0.85 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL1202307 | 0.84 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL1903665 | 0.84 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL1202768 | 0.83 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| Hydrochloric Acid SCHEMBL2763475 | 0.82 | AKR1C3 (0.58) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL1202770 | 0.82 | AKR1C3 (0.55) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773315-B1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | PSEN2, PSEN1, NAT1 | AKR1C3 521/4885AKR1C2 476/4885AKR1B10 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.